Surgical treatment of prostate cancer
DOI: https://doi.org/10.22591/magyurol.2023.2.becsia.85
Authors:
Bécsi Áron dr., Kubik András dr.
Semmelweis Egyetem, Urológiai Klinika és Andrológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
Summary
In Hungary, prostate cancer is the third most common cause of death in men with 4,500-4,800 newly diagnosed patients annually. The incidence is below the European average, but its mortality is much higher, which can also be explained by the lack of early detection.
Early detected prostate cancer can be cured, the 5-year survival is almost 100%, while in metastatic form it is only 28%. There are several treatment options available for prostate cancer. However, as a curative and life-expectancy-enhancing therapy, only total prostatectomy can be recommended for high-risk patients with the life expectancy of at least 10 years. During radical prostatectomy, the prostate is removed, along with its capsule, seminal vesicles on both sides and pelvic lymph nodes. During surgery, efforts must be made to preserve urinary continence and erectile function.